Abstract
The receptor for advanced glycation end products (RAGE) binds amyloid peptides with high affinity. Soluble RAGE-like peptides and Aβ-like peptides occur in relatively high concentrations in the circulation of individuals with Alzheimers disease. Protein complexes with epitopes for both Aβ and RAGE are also present. At physiological concentrations, forms of Aβ have different, but relatively low potencies as cytotoxicants in neural cells in culture. The purpose of this study was to determine whether a synthetic peptide complex composed of Aβ1-42 and RAGE23-54, a conserved Nterminal fragment of RAGE, exhibited increased cytotoxicity in comparison with the constituent peptides. Western analysis indicated that Aβ1-42 and RAGE23-54 remained primarily in their original low molecular weight states (4-6 kDa) during the maintenance of the individual peptides (37 ° C) in water from 1 to 4 weeks. In contrast, over the same maintenance periods the combined Aβ1-42 and RAGE23-54 peptides shifted to higher molecular weight complexes (up to 80-120 kDa). Protein complexes of similar molecular weights with epitopes for Aβ and RAGE antibodies were identified in human plasma. Incubation of differentiated PC-12 cells with 10-100 μM Aβ1-42 or with RAGE23-54 resulted in concentration-dependent decreases in cell viability. The cytotoxicity of each peptide was slightly enhanced by the progressive maintenance of Aβ1- 42 and RAGE23-54 in water over 3 weeks prior to the assay. Under the same conditions, the Aβ1-42 - RAGE23-54 complex became significantly more cytotoxic. These results suggest that the formation of soluble Aβ-RAGE complexes in Alzheimers disease could represent a mechanism for enhancing the neurotoxicity of amyloid peptides.
Keywords: Amyloid, glycation end products, mitochondrial function, cultured cells, protein complexes
Current Alzheimer Research
Title: Cytotoxicity of Aβ 1-42, RAGE23-54, and An Aβ -RAGE Complex in PC-12 Cells
Volume: 4 Issue: 5
Author(s): Shyamala Mruthinti, Nicholas Capito, Ajay Sood and Jerry J. Buccafusco
Affiliation:
Keywords: Amyloid, glycation end products, mitochondrial function, cultured cells, protein complexes
Abstract: The receptor for advanced glycation end products (RAGE) binds amyloid peptides with high affinity. Soluble RAGE-like peptides and Aβ-like peptides occur in relatively high concentrations in the circulation of individuals with Alzheimers disease. Protein complexes with epitopes for both Aβ and RAGE are also present. At physiological concentrations, forms of Aβ have different, but relatively low potencies as cytotoxicants in neural cells in culture. The purpose of this study was to determine whether a synthetic peptide complex composed of Aβ1-42 and RAGE23-54, a conserved Nterminal fragment of RAGE, exhibited increased cytotoxicity in comparison with the constituent peptides. Western analysis indicated that Aβ1-42 and RAGE23-54 remained primarily in their original low molecular weight states (4-6 kDa) during the maintenance of the individual peptides (37 ° C) in water from 1 to 4 weeks. In contrast, over the same maintenance periods the combined Aβ1-42 and RAGE23-54 peptides shifted to higher molecular weight complexes (up to 80-120 kDa). Protein complexes of similar molecular weights with epitopes for Aβ and RAGE antibodies were identified in human plasma. Incubation of differentiated PC-12 cells with 10-100 μM Aβ1-42 or with RAGE23-54 resulted in concentration-dependent decreases in cell viability. The cytotoxicity of each peptide was slightly enhanced by the progressive maintenance of Aβ1- 42 and RAGE23-54 in water over 3 weeks prior to the assay. Under the same conditions, the Aβ1-42 - RAGE23-54 complex became significantly more cytotoxic. These results suggest that the formation of soluble Aβ-RAGE complexes in Alzheimers disease could represent a mechanism for enhancing the neurotoxicity of amyloid peptides.
Export Options
About this article
Cite this article as:
Mruthinti Shyamala, Capito Nicholas, Sood Ajay and Buccafusco J. Jerry, Cytotoxicity of Aβ 1-42, RAGE23-54, and An Aβ -RAGE Complex in PC-12 Cells, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018325
DOI https://dx.doi.org/10.2174/156720507783018325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Current Pharmaceutical Biotechnology Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Case Series Describing an Outbreak of Highly Resistant Vancomycin Staphylococcus aureus (Possible VISA/VRSA) Infections in Orthopedic Related Procedures in Guatemala
Infectious Disorders - Drug Targets Important Role of Relaxation Techniques in Immune Functions, Glycemic Control, and Stress in Diabetic Patients with COVID-19: A Review
Current Diabetes Reviews Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Co-morbidity of Diabetes Mellitus and Orodental Diseases in Nigeria
Current Diabetes Reviews Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Case Report: Escherichia fergusonnii - Pathogen in Urinary Tract Infection
Infectious Disorders - Drug Targets Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design Therapeutic Potential of the Mammalian Pyruvate Dehydrogenase Kinases in the Prevention of Hyperglycaemia
Current Drug Targets - Immune, Endocrine & Metabolic Disorders